ArticleOncotarget2016
Liposomal bortezomib is active against chronic myeloid leukemia by disrupting the Sp1-BCR/ABL axis.
Xiaojuan Yang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
8 papers cite it
this papercites it
ArticleOncotarget2016
Xiaojuan Yang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.